Answers are grounded in this paper and cite their sources.
Overexpression of the nucleotide‐binding leucine‐rich repeat protein 3 (NLRP3) inflammasome in chronic auto‐immune diseases leads to skeletal anomalies, with severe osteopenia due to the activation of osteoclasts. Reproducing this phenotype inNlrp3knock‐in mice has provided insights into the role of NLRP3 in bone metabolism. We studied the role of NLRP3 in physiological bone development using a completeNlrp3knock‐out mouse model. We found impaired skeletal development inNlrp3−/−mice, resulting in a shorter stature than that ofNlrp3+/+ mice. These growth defects were associated with altered femur bone growth, characterized by a deficient growth plate and an osteopenic profile of the trabeculae. No differences in osteoclast recruitment or activity were observed. Instead, Nlrp3−/−femurs showed a less mineralized matrix in the trabeculae than those ofNlrp3+/+ mice, as well as less bone sialoprotein (BSP) expressing hypertrophic chondrocytes. In vitro, primary osteoblasts lacking NLRP3 expression showed defective mineralization, together with the downregulation of BSP expression. Finally, follow‐up by micro‐CT highlighted the role of NLPR3 in bone growth, occurring early in living mice, as the osteopenic phenotype diminishes over time. Overall, our data suggest that NLRP3 is involved in bone edification via the regulation of hypertrophic chondrocyte maturation and osteoblast activity. Furthermore, the defect appeared to be transitory, as the skeleton recovered with aging.
No takes yet. Share an insight, caveat, or question.
Detzen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: